Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Cancer|April 15, 2020
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancerPierFranco Conte, Andreas Schneeweiss, Sibylle Loibl, et al.
JCO Global Oncology|October 22, 2025
Budget Impact of the Oncotype DX Test in Early-Stage Breast Cancer for the Brazilian Private Health Care SystemCarlos Alberto da Silva Magliano, Ivan R Zimmermann, Leandro Jonata de Carvalho Oliveira, et al.
Clinical Breast Cancer|August 7, 2025
Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of BrazilAline Coelho Gonçalves, Tomas Reinert, Heloisa Mussato Fernandes da Cruz, et al.
JCO Global Oncology|January 30, 2026
Cost-Effectiveness of the Oncotype DX Breast Recurrence Score Test in the Brazilian Private Health Care SectorIvan Zimmermann, Carlos Alberto da Silva Magliano, Leandro Jonata de Carvalho Oliveira, et al.
JCO Global Oncology|November 9, 2022
Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in BrazilCristiano A A Resende, Heloísa M Fernandes Cruz, Matheus Costa E Silva, et al.
Breast (Edinburgh, Scotland)|December 11, 2017
Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancerSaulo Brito Silva, Allan Andresson Lima Pereira, Gustavo Nader Marta, et al.
The Oncologist|March 29, 2022
Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast BrazilMaryam Nemati Shafaee, Leonardo Roberto Silva, Susana Ramalho, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINEE P Mamounas, M Untch, M S Mano, et al.
The New England Journal of Medicine|December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Breast Cancer Research and Treatment|July 31, 2020
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)Daniela Dornelles Rosa, José Bines, Gustavo Werutsky, et al.
Pageof 9